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o5% and platelet counts are not elevated. By strictly adhering
to the 2008 WHO criteria, we provide important molecular
information in a relatively homogenous and well-deﬁned group
of patients. Morphological diagnoses are often subjective, with
inter-observer variability, and inaccurate classiﬁcation of myeloid
neoplasms can result in erroneous estimation of associated
molecular abnormalities. Speciﬁcally, it is important to note that
BM ring sideroblasts are sometimes seen in both PMF and ET,
and it is possible to misdiagnose some of these cases as RARS-T
or RARS.10,11
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The germline sequence variant rs2736100_C in TERT associates
with myeloproliferative neoplasms
Leukemia (2014) 28, 1371–1374; doi:10.1038/leu.2014.48
Myeloproliferative neoplasms (MPN) constitute a group of clonal
hematological disorders characterized by an expansion and
accumulation of one or more mature cell types of the myeloid
lineages. There are four main groups of MPNs that can be
classiﬁed by the presence or absence of the Philadelphia (Ph)
chromosome.1 Chronic myeloid leukemia is accompanied by the
Ph chromosome, whereas polycythemia vera (PV), essential
thrombocythemia (ET) and primary myeloﬁbrosis (PMF) are not.1
In all three Ph-negative MPN subtypes (hereafter called MPN), a
recurrent somatic mutation is frequently found in the
pseudokinase region of Janus kinase 2 (JAK2V617F).2 The
mutation is observed in about 80–95% of PV cases, 50% of ET
cases and 60% of PMF cases.2 Owing to the activating nature of
the mutation, it leads to constant stimulation of myeloid
proliferation.2 Family studies have shown that germline variants
may predispose to the disease as the risk of MPN among ﬁrst-
degree relatives of MPN patients in Sweden is ﬁve to sevenfold
greater than that in the general population.2 Furthermore,
common germline single-nucleotide polymorphisms (SNPs) at
the JAK2 locus have been associated with MPN.3–5
The aim of the current study was to search for germline
sequence variants that associate with risk of MPNs by performing
genome-wide association analysis. For the association analysis, we
used sequence variants identiﬁed by whole genome sequencing
(WGS), to an average depth of 22 , of DNA isolated from white
blood cells of 2230 Icelanders (Supplementary Material). Using
imputation assisted by long-range haplotype phasing, the
genotype probabilities of all the 34.2 million sequence variants
identiﬁed were determined for Icelanders genotyped with Illumina
(San Diego, CA, USA) SNP chips. Furthermore, using Icelandic
genealogical information, genotype probabilities were calculated
for individuals who are close relatives of chip-typed individuals
(familial imputation) (Supplementary Material). We then tested the
identiﬁed variants for association with MPN, using 237 Icelanders
diagnosed with MPN, including PV (n¼ 98), ET (n¼ 40), PMF
(n¼ 26) and 34 128 Icelandic controls with imputed genotypes
(Table 1 and Supplementary Table S1). It is worth stressing that
somatic MPN mutations do not affect the association analysis as
the variants identiﬁed through WGS and subsequently imputed
into MPN cases are almost exclusively from individuals not
diagnosed with MPN (one MPN case, diagnosed 9 years after
blood draw, among the 2230 sequenced individuals).
Assuming a multiplicative model, we observed a genome-wide
signiﬁcant association between MPN in the Icelandic population
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and a common variant rs2736100_C located in the second intron
of the TERT gene at the TERT-CLPTM1L locus (allele frequency
(AF)¼ 49.3%, odds ratio (OR)¼ 2.09, P-value¼ 6.39 10 10)
(Figure 1 and Table 1). In addition, we replicate the association
of rs10974944_G in JAK2 previously reported to associate
with MPN5 (AF¼ 28.7%, OR¼ 1.78, P-value¼ 1.90 10 6;
Supplementary Table S2) and detect an even stronger association
between MPN and a second variant, rs1034072_A, in JAK2
(AF¼ 28.2%, OR¼ 1.85, P-value¼ 3.19 10 7; Table 1). This
variant is highly correlated with rs10974944_G (r2¼ 0.91;
Supplementary Table S2). As reported for rs10974944_G, the
association of the JAK2 variant rs1034072_A with PV (OR¼ 2.76) is
stronger than that with the other MPN subphenotypes
(ET, OR¼ 1.39 and PMF, OR¼ 1.56)5 (Table 1). In contrast, the
effect of the risk allele of rs2736100_C at the TERT-CLPTM1L locus
is similar for the three MPN subphenotypes, with OR 2.32 (PV), 2.25
(ET) and 2.42 (PMF) (Table 1).
We tested all variants at the TERT-CLPTM1L locus that associate
with MPN with a P-valueo1 10 5 and those that have been
associated with cancer and idiopathic pulmonary ﬁbrosis,6,7
conditioning on rs2736100. None of these SNPs remained
signiﬁcantly associated with MPN after conditioning the
association on rs2736100 (Supplementary Table S3). This raises
the possibility that rs2736100 is the causative variant at this locus
as the association was based on WGS data and therefore, all
simple variants at this locus were tested.
In a recent publication, rs2736100_C is one of the eight variants
that were shown to associate with long telomeres in white blood
cells,8 suggesting that this SNP acts on the TERT gene encoding
the reverse transcriptase of the telomerase complex essential for
maintaining the telomere length. To our knowledge, functional
effect of rs2736100 has not been evaluated. However, for
rs7705526, an SNP located 542 bp telomeric to rs2736100 and
the variant at the TERT-CLPTM1L locus that shows the highest
correlation with rs2736100 (r2¼ 0.52; Supplementary Table S3), an
increased enhancer activity has been described for the allele
correlated with rs2736100_C.9 Therefore, rs2736100_C might
increase transcription of TERT through increased enhancer
activity and this enhanced expression could mediate the MPN risk.
It is well documented that MPN cells have shorter telomeres
than normal cells10 as do cells in many types of neoplasms.11 Short
telomeres have been proposed to promote tumor formation by
inducing genomic instability. The association of TERT rs2736100_C
with increased risk for MPN and with longer telomeres thus
appears to be a paradox. However, the biology of the TERT gene
and its link to cancer (including MPN) is complicated and could
Figure 1. Genome-wide association results for MPN case (N¼ 237) and control (N¼ 34 128) analysis in Iceland. The  log10 of the allelic
P-values o0.05 for the 34.2 million sequence variants tested is presented. The chromosomal distribution is shown as a Manhattan plot.
Table 1. Association of the TERT variant rs2736100_C and the JAK2 variant rs1034072_A with MPN in Icelandic samples
Phenotype TERT rs2736100_C JAK2 rs1034072_Aa
N P-value OR P-value OR
MPN (Ph-negative) 237 6.39 10 10 2.09 3.19 10 7 1.85
Polycythemia vera 98 1.10 10 5 2.32 8.03 10 8 2.76
Essential thrombocythemia 40 2.87 10 3 2.25 0.25 1.39
Primary myelofibrosis 26 2.46 10 2 2.42 0.27 1.56
Abbreviations: ET, essential thrombocythemia; JAK, janus kinase; MPN, myeloproliferative neoplasm; OR, odds ratio; PMF, primary myelofibrosis. Of the 237
MPN cases, 74 were diagnosed as MPN unclassifiable and 1 MPN case had two sub-phenotypes assigned. Risk allele frequency for TERT rs2736100 is 49.32%;
risk allele frequency for JAK2 rs1034072 is 28.21%. ars1034072 is the strongest signal at the JAK2 locus in our data and it is highly correlated (r2¼ 0.91) with the
previously reported JAK2 germline variant rs10974944.
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even be mediated through functions other than telomerase-
mediated extensions of telomeres such as its effect on cell DNA
repair, cycle regulators or on cell signaling.12 This hypothesis is
further supported by a lack of association with MPN of
rs10936599_C in the TERC gene (template-containing telomerase
RNA that is part of the telomerase complex; Supplementary Table
S4) that shows the strongest reported genome-wide association
with increased telomere length.8
An association of TERT rs2736100_C was observed in Iceland
with an increase in red blood cell counts similar to a previous
report13 (effect (s.d.)¼ 0.019, P-value¼ 9.07 10 6, N¼ 76 739
individuals; Supplementary Table S5). In addition, we observed
an association with elevated platelet counts (effect (s.d.)¼ 0.025,
P-value¼ 5.26 10 8, N¼ 103441 individuals) and white blood
cell counts (effect (s.d.)¼ 0.016, P-value¼ 4.10 10 4, N¼ 126 853
individuals). The association with white blood cell counts is limited
to cells of the myeloid linage (Supplementary Table S5) and the
effect on blood cell counts remained unchanged after excluding
MPN cases. In addition to the association of rs2736100_C with the
three subphenotypes of MPN, these results for the blood cell
counts indicate that the TERT variant asserts its effect on a
common myeloid progenitor. As this effect on cell counts is seen in
individuals without MPN it could mean that the risk of MPN
conferred by the variant is mediated through an effect on cell
numbers. In line with no effect on lymphocyte counts,
rs2736100_C did not associate with lymphoproliferative malig-
nancies (Supplementary Table S6). In contrast to the TERT variant,
the germline JAK2 risk variant rs1034072_A is not associated with
red blood cell count (P-value¼ 0.91, effect (s.d.)¼ 0.001, N¼ 76 739
individuals), but associates with decrease in platelet count (P-
value¼ 2.50 10 4, OR¼  0.019, N¼ 103441 individuals)
(Supplementary Table S5). This might indicate that TERT and
JAK2 predispose to MPN through different mechanisms.
The recurrent somatic mutation JAK2V617F is present in a large
fraction of MPN cases.2 We analyzed available blood samples from
Icelandic MPN cases (N¼ 103) for the JAK2V617F somatic mutation
using a real-time quantitative-PCR assay (Supplementary Material).
We excluded blood samples drawn more than 2 years before MPN
diagnosis (N¼ 43). In the remaining samples (N¼ 62) we observed
positive JAK2V617F somatic mutation status in 69.4% of MPN cases
and 80.6% of PV cases (N¼ 31) (Supplementary Table S7), in line
with previous studies.2 The germline MPN risk allele in JAK2,
rs10974944_G, has been shown to associate with increased allelic
burden of the JAK2V617F somatic mutation.14 We tested the counts
of the MPN risk alleles rs1034072_A in JAK2 and rs2736100_C in
TERT for correlation with JAK2V617F allele burden. We observed a
signiﬁcant correlation between the number of germline risk alleles
and allelic burden of JAK2V617F at the JAK2 locus (P¼ 0.02,
effect¼ 10.28% of allelic burden per germline risk allele) but not at
the TERT locus (P¼ 0.77) (Supplementary Table S8). However,
owing to our small MPN sample set, a weak effect of the germline
TERT variant on JAK2V617F allele burden cannot be excluded.
Recurrent somatic mutations in the TERT promoter region, C228T
and C250T, shown to increase TERT expression, have recently
been reported in several cancer types.15 We screened for these
mutations by Sanger sequencing in the MPN cases used for
screening the JAK2V617F mutation (N¼ 62) and observed only a
single occurrence of the the C228T TERT mutation.
In conclusion, we report a common germline variant in TERT that
associates with MPN. The risk mediated by the variant rs2736100_C
is large (OR¼ 2.09) and in our data even larger than the reported
JAK2 germline signal rs1034072_A (OR¼ 1.85). As the TERT variant is
more common than the JAK2 variant (49.3% vs 28.2%) its
population attributable risk is larger (57.7% vs 34.9%). Unlike the
JAK2 variant, the TERT variant exerts similar risk on the three MPN
subtypes PV, ET and PMF. Our data also suggest that the germline
TERT variant does not associate with the recurrent somatic
JAK2V617F mutation. Association of the TERT variant with increased
counts of myeloid white blood cells, red blood cells and platelets
but not lymphoid cells, in the general population, together with
similar effects on all three subpopulations of MPN suggests that the
variant exerts its effect on hematopoiesis by increasing proliferation
of cells derived from common myeloid progenitor.
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Low rate of calreticulin mutations in refractory anaemia with ring
sideroblasts and marked thrombocytosis
Leukemia (2014) 28, 1374–1376; doi:10.1038/leu.2014.49
Refractory anaemia with ring sideroblasts (RARS) and marked
thrombocytosis (RARS-T) was proposed in the World Health
Organisation 2001 classiﬁcation of tumours of haematopoietic
and lymphoid tissues and retained as a provisional entity in the
2008 version.1 RARS-T is characterised by a high rate of JAK2V617F
mutations2–4 or the presence of mutations in exon 10 of MPL
(myeloproliferative leukaemia).5,6 The existence of RARS-T as an
entity independent from RARS and essential thrombocythemia
(ET) was a matter of debate, as certain specialists favoured the
hypothesis that RARS-T was a form of ET with 415% of ring
sideroblasts in the bone marrow, whereas others thought that
RARS-T is derived from RARS with secondary thrombocytosis
developing through the acquisition of the JAK2V617F mutation.
We recently demonstrated that RARS-T differed from RARS and
ET from a clinical, biological and prognostic point of view.4 The
presence of high rates of splicing factor 3B subunit 1 (SF3B1)
mutations in RARS-T and the absence of these mutations in ET
strengthened the hypothesis that RARS-T was a distinct entity.7–9
However, the myeloproliferative features of RARS-T are not totally
explained by JAK2V617F and MPLW515L mutations, as these account
for only 50% and 1% of RARS-T, respectively. The question remains
about other causative mutations responsible for the myeloproli-
ferative part of RARS-T. The challenge is the same in myeloproli-
ferative neoplasms (MPN), as 50–60% of ET and primary
myeloﬁbrosis (PMF) do not present with any JAK2 orMPLmutations.
The recent discovery of a high rate of calreticulin (CALR)
mutations in JAK2-non-mutated MPNs was a great step towards
better understanding of the molecular pattern of these diseases.
Mutations in exon 9 of CALR have been reported as mutually
exclusive of JAK2 and MPL mutations, and found in 67–71% of ET
and 56–88% of PMF with wild-type JAK2 or MPL.10,11 These
mutations are insertions or deletions leading to a frameshift
responsible for modifying the C-terminal part of the protein.
Following these modiﬁcations, the C-terminal part of the protein
becomes positively charged and the reticulum targeting KDEL
sequence is abrogated, which disturbs its cellular localisation.
Up to now, CALR mutations have only been explored in small
RARS-T cohorts, with a mutation frequency ranging from 0 to
12.5%.10,11 The purpose of our study was to analyse the frequency
of CALR mutations in a large RARS-T cohort in order to determine
whether CALR mutations may also be responsible for
thrombocytosis in this disease. We therefore analysed a large
cohort of 95 RARS-T patients, with 29 RARS as the control.
According to the WHO 2008 classiﬁcation, patients are
diagnosed with RARS-T if they fulﬁl the following criteria:
i) anaemia (haemoglobin level o125 g/l for females and
o135 g/l for males) with erythroid dysplasia and 415% ring
sideroblasts; ii) thrombocytosis with 4450 109 platelets/l; iii)
o5% blast cells in the bone marrow; iv) presence of large atypical
megakaryocytes similar to those observed in BCR-ABL1-negative
MPN; v) no secondary cause of ring sideroblasts; and vi)
no karyotype abnormalities such as del(5q), t(3;3)(q21;q26)
or inv(3)(q21q26).1 One hundred and twenty-four samples
including 95 RARS-T and 29 RARS from seven European centres
in three European countries were collected and tested. This cohort
has been published previously.4,9
For each patient, demographic (gender and age at diagnosis) and
biological data (blood cell count, bone marrow exploration, ring
sideroblasts, karyotype and molecular explorations) were collected.
The SF3B1 mutations were analysed with a sensitive next-
generation amplicon deep-sequencing assay (454 Life Sciences,
Branford, CT, USA) with a median coverage of 500 reads. This
approach was able to detect mutations with a sensitivity below 1%.9
The JAK2V617F mutation was analysed by allele-speciﬁc real-time
PCR to estimate the allele burden according to the method
published by Lippert et al.12 with a sensitivity of 1%. JAK2 exon 12
analysis was performed according to the method by Schnittger
et al.13 and the MPLW515 mutations were analysed by high-
resolution melting curve analyses followed by Sanger sequencing
if positive, as previously published by Schnittger et al.14
The CALR exon 9 mutations were screened by fragment analysis
and Sanger sequencing according to the method by Klampﬂ et al.10
Approval for the study was obtained from the ethics committee
of each institution and the procedures were carried out in
accordance with the Helsinki Declaration of 1975, as revised
in 2000.
A total of 124 cases with 95 RARS-T and 29 RARS (including 62
males and 62 females) were recorded in the study, which is, to our
best knowledge, the largest series of myelodysplastic syndromes
with ring sideroblasts (MDS-RS) studied for CALR mutations. The
median age at diagnosis was 74 years and 73 years for the RARS-T
and RARS cohort, respectively (Table 1). A karyotype was available
in 112 cases (87 RARS-T and 25 RARS). Seventy-ﬁve (86.2%) RARS-T
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